Kelun-Biotech's New Milestone in Lung Cancer Therapy
Chengdu, China - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) has made significant strides in cancer treatment with its announcement regarding the Phase III clinical study, OptiTROP-Lung05, which involves its treatment, sacituzumab tirumotecan (sac-TMT), in combination with KEYTRUDA (pembrolizumab). This groundbreaking study primarily focused on patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) and has yielded promising results, showing a statistically significant improvement in progression-free survival (PFS), marking a pivotal moment in cancer research.
Understanding the Clinical Study and Its Results
The Phase III trial, OptiTROP-Lung05, was designed to compare the efficacy of sac-TMT alongside pembrolizumab against pembrolizumab alone in treating patients suffering from locally advanced or metastatic NSCLC. The findings from the interim analysis showed not only a notable enhancement in PFS for those receiving the combined treatment but also hinted at a positive trajectory for overall survival rates.
This achievement is particularly significant as it represents the first time that an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor has met its primary endpoint in the first-line treatment of this type of lung cancer. Following these results, Kelun-Biotech is gearing up to engage in discussions with the appropriate regulatory authorities in China to explore the possibility of submitting a supplemental new drug application (sNDA) for sac-TMT, highlighting its potential to reshape treatment protocols for lung cancer.
About Sac-TMT and Its Mechanism of Action
Sac-TMT is already recognized for its effectiveness in patients with EGFR-mutant NSCLC, particularly in later treatment lines. It has demonstrated dual advantages in both PFS and overall survival when compared to standard platinum-based chemotherapy, marking it as a leader in the ADC space. The unique mechanism of sac-TMT involves a targeted approach to destroy cancer cells, utilizing a specific linker to deliver a topoisomerase I inhibitor payload directly to tumor cells. This selectiveness not only enhances its effectiveness but also reduces potential harm to surrounding healthy tissues.
Future Prospects for Sac-TMT in Oncology
Currently, sac-TMT is being assessed across multiple registrational studies, both in China and globally. The company is actively tracking its performance through ten ongoing registrational studies in lung cancer. Notably, five of these studies are located in China while the other five are global Phase III trials. This extensive research effort underscores the commitment to advance sac-TMT's application in oncology and potentially expediting its availability to a broader patient demographic.
Expansion of Sac-TMT's Applications
In addition to its current approvals in treating various forms of NSCLC, sac-TMT is also progressing through the regulatory landscape for additional indications, including its application for triple-negative breast cancer (TNBC). Following an accepted sNDA for treatment in adults with advanced HR+/HER2- BC who have undergone previous therapies, sac-TMT continues to gain recognition as an innovative solution for complex therapeutic challenges in oncology.
About Kelun-Biotech
Kelun-Biotech (6990.HK) serves as a key player in the biopharmaceutical sector, emphasizing research and development along with the manufacturing of groundbreaking drugs. The company specializes in addressing significant health challenges present in solid tumors and other complex conditions while fostering collaborations that expand its reach beyond local markets. At present, Kelun-Biotech boasts over 30 ongoing innovative projects, of which several have already gained market approval.
With a strong foundation in proprietary ADC technology and multiple clinical projects underway, Kelun-Biotech is well-positioned to contribute to the global pharmaceutical landscape while continually striving to meet unmet medical needs in various therapeutic areas.
Frequently Asked Questions
What is sac-TMT?
Sac-TMT is a novel antibody-drug conjugate developed by Kelun-Biotech aimed at treating advanced solid tumors, particularly in lung cancer.
What were the results of the Phase III study?
The study demonstrated a statistically significant improvement in progression-free survival for patients treated with sac-TMT alongside KEYTRUDA compared to pembrolizumab alone.
Is sac-TMT approved for use?
Yes, sac-TMT is currently approved in China for certain indications in NSCLC and TNBC, with ongoing studies for wider applications.
Who is Kelun-Biotech?
Kelun-Biotech is a subsidiary focused on developing innovative biological and small-molecule drugs, addressing major disease areas and aiming for global impact.
What are the future plans for sac-TMT?
The company aims to continue clinical trials to explore further potential indications for sac-TMT, enhancing its treatment options for various cancers.
